Reviews Supplements AMD Management : Page 1

AMD Management Era of Genetic Testing ge-related macular degeneration (AMD) is the leading cause of visual loss in the elderly in the United States. Several genetic variants, as well as modi fi able factors such as smoking, lower intake of dietary antioxidants and Omega-3 fatty acids, as well as higher body mass index (BMI) are known to be associated with higher rates of progression from the early to advanced stages of AMD. 1–3 The complexity of this disease has really become apparent lately, making it necessary for eyecare professionals to embrace available genetic tests as well as other emerging tests to truly understand how we can bene fi t our patients now and in the future. Recently, fi ve leading optometrists gathered to discuss the mainstream management of patients with AMD in the era of genetic testing. In this continuing education monograph, they share their experiences and opinions as they relate to the clinical aspects of diagnosis and risk assessment. UNDERSTANDING AND DEFINING AMD Jeffry D. Gerson, O.D.: In the United States, as many as 11 million people have some form of AMD and that number is expected to double to nearly 22 million by 2050. 4 What do you use in your practices as a de fi nition of macular degeneration? Kirk L. Smick, O.D.: I think the de fi nition varies depending on whether you are an academic or a clinician. As a clinician, I am going to decide on tests and a follow-up schedule based strictly on the clinical appearance, regardless of what the text-book de fi nition says. Mark T. Dunbar, O.D.: When a patient comes in with numer-ous drusen or has retinal pigment epithelium (RPE) change, of course you call it macular degeneration, but how early can you see it clinically and make that call? Another point to consider Supported by Release Date: December 2012 Expiration Date: November 30, 2013 Goal Statement: Age-related macular degeneration (AMD) is the leading cause of legal blindness in Americans aged 55 years and older. Genetic tests can predict an individual’s risk for developing advanced AMD and may prompt optometrists to examine high-risk AMD patients more frequently. This course reviews the clinical aspects of diagnosis and risk management, as well as patient management, and also discusses the latest related fi ndings in genetic research. Faculty/Editorial Board: Mark T. Dunbar, O.D., Jeffry D. Gerson, O.D., Gary Morgan, O.D., Diana L. Shechtman, O.D., Kirk L. Smick, O.D. Credit Statement: This course is COPE approved for 2 hours of CE credit. COPE ID is 36301-PS. Please check your state licensing board to see if this approval counts toward your CE requirement for relicensure. Joint-Sponsorship Statement: This continuing education course is joint sponsored by the University of Alabama School of Optometry and ArcticDx. Disclosure Statement: Dr. Dunbar has received honorariums from Allergan, Carl Zeiss Meditec, Alcon Nutritional, ArcticDx and Reed Exhibi-tion. Dr. Gerson is an advisory board member for ArcticDx. Dr. Morgan is an advisory board Member for ArcticDx. Dr. Shechtman has received honorariums from Alcon, Allergan, ArcticDx, Carl Zeiss, Bausch + Lomb and ZeaVision. Dr. Smick is an advisory board member for ArcticDx. in the A Sponsored by an educational grant from

Next Page

Publication List
Using a screen reader? Click Here